Please assess the completion status of the following clinical trial:

Trial Title: Consolidation Therapy With Hu3S193 for Women With Ovarian, Primary Peritoneal or Fallopian Tube Cancer

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. The Informed Consent Form (ICF) must be signed before the performance of any study specific procedure or treatment.~2. Female patients of \>= 18 years of age.~3. Relapsing ovarian adenocarcinoma, fallopian tubes or primary peritoneal who achieved a complete clinical response after the first treatment of relapse with platinum-based regimen. A complete response is defined as the absence of cancer related symptoms, normal physical exam, normal CA-125 (tumor marker) level, normal chest X-ray and CT-scan of abdomen/pelvis. Eligibility allows the presence of nonspecific findings as long as not showing clear evidence of disease such as: lymph node and/or soft tissue abnormalities \<= 1.0 cm which are frequently present on the pelvis and will not be considered to be a conclusive evidence of disease.~4. Expression of antigen Ley documented by immunohistochemistry of archived primary or metastatic tumor samples.~5. The patient must have been submitted at least to hysterectomy and bilateral salpingo-oophorectomy before entering the study and must have received platinum-based chemotherapy as adjunctive or neo-adjunctive treatment at the first presentation.~6. At least 5 and no more than 8 cycles of platinum combination therapy (i.e. doublet) as treatment for the first relapse.~7. All side effects from chemotherapy must have been resolved or must be grade 1.~8. Interval between the last dose of the treatment with platinum that achieved clinical CR (complete response) and the first dose of Hu3S193 =\< 8 weeks.~9. Karnofsky performance status \>= 70%.~10. Results of laboratorial exams in the first 2 weeks before drug infusion within the following values:~    * Absolute Neutrophil Count \>= 1.5 x 10x3 / mm3~   * Platelet count \>= 100 x 10x3 / mm3~   * Blood bilirubin \<= 2.0 mg/dL~   * Aspartate aminotransaminase (AST) and Alanine aminotransferase (ALT) \<= 2.5 x upper limit of normal (ULN).~   * Blood creatinine \<= 2.0 mg/dL.~   * Prothrombin time \< 1.3 x control~11. Expected survival \>= 12 months.~12. Patients must be willing to participate and be able to comply with the protocol throughout the study.~Exclusion Criteria:~1. Mucinous or clear cell histology.~2. Patients must not have received Bevacizumab as part of their treatment on relapse.~3. Diagnosis of primary tumor relapse made exclusively based on elevated levels of serum CA-125 with values \<2-fold the upper limit of normality.~4. Concomitant use of systemic corticosteroids or immunosuppressive agents.~5. Known CNS (central nervous system) involvement by tumor.~6. Clinically significant heart disease (New York Heart Association Class III or IV).~7. ECG indicating clinically significant arrhythmia.~8. History of myocardial infarction within 6 months.~9. Other serious diseases, (e.g.: serious infections requiring antibiotics, bleeding disorders, chronic inflammatory bowel disease, or diseases that may interfere in the obtainment of accurate study results).~10. Radiotherapy treatment, radiopharmaceuticals (e.g. 32P), biological therapy, anti-estrogen therapy (including tamoxifen), immunotherapy or surgery within 4 weeks before the first administration of investigational product fail to recover from toxic effects of any of these therapies within 6 weeks prior to study inclusion.~11. Exposure to any investigational product within 4 months prior to study inclusion.~12. Previous treatment with a humanized murine antibody and/or fragment of such antibody.~13. Previous history of tumor (excluding appropriately treated non-melanoma skin cancer or carcinoma in situ of the cervix or no evidence of disease within at least 5 years for previous breast cancer or stage I endometrial cancer).

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Monoclonal antibody hu3S193 (Type: EXPERIMENTAL): Monoclonal antibody hu3S193 will be administered to 51 patients at the dose of 30mg/m2 every other week (total of 12 infusions) for a total of 23 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).